Evidence map›Paper›PMID 36884195›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023

Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases.

Deepika Negi, Simon Granak, Susan Shorter, Valerie B O'Leary, Ivan Rektor, Saak V Ovsepian

Open access · hybridAbstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Deepika NegiFaculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, UK.
Simon GranakNational Institute of Mental Health, Topolova 748, Klecany, 25067, Czech Republic.
Susan ShorterFaculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, UK.
Valerie B O'LearyDepartment of Medical Genetics, Third Faculty of Medicine, Charles University, Ruská 87, Prague, 10000, Czech Republic.
Ivan RektorFirst Department of Neurology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Saak V OvsepianFaculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, UK. s.v.ovsepian@gre.ac.uk.ORCID 0000-0002-9522-4159
University of Greenwich · GBCentral European Institute of Technology · CZCharles University · CZNational Institute of Mental Health · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In neurodegenerative diseases, changes in neuronal proteins in the cerebrospinal fluid and blood are viewed as potential biomarkers of the primary pathology in the central nervous system (CNS). Recent reports suggest, however, that level of neuronal proteins in fluids also alters in several types of epilepsy in various age groups, including children. With increasing evidence supporting clinical and sub-clinical seizures in Alzheimer's disease, Lewy body dementia, Parkinson's disease, and in other less common neurodegenerative conditions, these findings call into question the specificity of neuronal protein response to neurodegenerative process and urge analysis of the effects of concomitant epilepsy and other comorbidities. In this article, we revisit the evidence for alterations in neuronal proteins in the blood and cerebrospinal fluid associated with epilepsy with and without neurodegenerative diseases. We discuss shared and distinctive characteristics of changes in neuronal markers, review their neurobiological mechanisms, and consider the emerging opportunities and challenges for their future research and diagnostic use.

Indexed as

Alzheimer DiseaseEpilepsyNeurodegenerative DiseasesAmyloid beta-PeptidesBiomarkersChildHumanstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAxonal degenerationEpileptic seizuresFluid biomarkersNeurodegenerationNeurofilament light chainNeurograninTau protein

Identifiers

PMID36884195
PMCPMC10275849
OpenAlexW4323534126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.